Clinical studies on ritipenem acoxil in respiratory tract infection

Abstract

We investigated the clinical efficacy and safety of ritipenem acoxil (RIPM-AC), a new oral penem antibiotic, in patients with respiratory tract infections.
A daily dose of 600-900mg of RIPM-AC was given orally for 7-15 days to 11 patients after a meal: 4 with pneumonia, 2 with chronic bronchitis and 5 with secondary infections to chronic respiratory disease.
The clinical efficacy was excellent in 2 patients, good in 7 and fair in 2, an efficacy rate of 81.8%.
Eight strains (3 strains of Haemophilus influenzae, 2 strains of Streptococcus pneumoniae and one strain each of Enterobacter aerogenes, Morganella morganii, Pseudomonas aeruginosa) were identified as causative organisms from sputum. Seven strains were eradicated, and the other one (P.aeruginosa) persisted.
Neither side effects nor abnormal laboratory findings were observed.